Duncan Jessica, Lee Stevens Patrick, Bigby Emily, Floyd Courtney, Malina Josh, Nickens Jennifer, Lambert Amber, Kantor Taylor
Ivim Health, 4200 Regent St, STE 200, Columbus, OH 43219, USA.
Obes Pillars. 2025 Jun 30;15:100188. doi: 10.1016/j.obpill.2025.100188. eCollection 2025 Sep.
Here we show results of 1,131 patients on therapy with semaglutide who underwent a comprehensive clinical protocol utilizing the Individualized Virtual Integrative Medicine (IVIM) approach, evaluating the protocol as a comprehensive clinical care model for patients utilizing GLP-1 medications.
This is a retrospective analysis of patients who completed at least 365 days of the protocol while on GLP-1 therapy with semaglutide. Patients with a body-mass index (BMI) of 30 or greater were included. Patients were prescribed personalized therapy with semaglutide based on their weight reduction goals, insurance coverage, accessibility during the GLP-1 shortages of branded semaglutide, and socioeconomic factors.
The cohort size was 1,131 patients who were prescribed semaglutide while on the IVIM protocol. A Linear Mixed Effects Model was used to test the relationship between time spent on the IVIM protocol and weight reduction. This model estimated a weight reduction coefficient of -0.739 lbs/week, providing a large z-statistic of -74.02 and a p value < 0.0001. Mean change in weight at 12-weeks for all patients was 14.9 lbs (6.5 %), 24-weeks: 28.6 lbs (12.6 %), 36-weeks: 36.8 lbs (16.4 %), 52-weeks: 45.95 lbs (19.5 %), and those who extended to 68-weeks lost: 46.9 lbs (21.8 %). The percentage of patients who lost at least 5 % of their body weight at 52 weeks was: 99.2 %, 10 % or more: 93.9 %, 15 % or more: 73.5 %, and 20 % or more: 47.8 %.
Patients with obesity completing 52 weeks of the IVIM clinical protocol on semaglutide lost 19.5 % of total body weight with 47.8 % of patients losing 20 % or more. The results of this study indicate the protocol is a novel method to enhance therapeutic medical weight reduction results via a structured, telehealth-based approach for obesity management.
在此，我们展示了1131例接受司美格鲁肽治疗的患者的结果，这些患者采用了个性化虚拟整合医学（IVIM）方法的综合临床方案，将该方案评估为使用GLP-1药物的患者的综合临床护理模式。
这是一项对在接受司美格鲁肽GLP-1治疗期间完成至少365天方案的患者的回顾性分析。纳入体重指数（BMI）为30或更高的患者。根据患者的减重目标、保险覆盖范围、在品牌司美格鲁肽GLP-1短缺期间的可及性以及社会经济因素，为患者开具个性化的司美格鲁肽治疗方案。
队列规模为1131例在IVIM方案期间开具司美格鲁肽的患者。使用线性混合效应模型来测试在IVIM方案上花费的时间与减重之间的关系。该模型估计减重系数为-0.739磅/周，提供了-74.02的大z统计量和p值<0.0001。所有患者在12周时的平均体重变化为14.9磅（6.5%），24周时：28.6磅（12.6%），36周时：36.8磅（16.4%），52周时：45.95磅（19.5%），而延长至并完成68周的患者减重：46.9磅（21.8%）。在52周时体重减轻至少5%的患者百分比为：99.2%，减轻10%或更多：93.9%，减轻15%或更多：73.5%，减轻20%或更多：47.8%。
完成司美格鲁肽IVIM临床方案52周的肥胖患者体重减轻了总体重的19.5%，47.8%的患者体重减轻了20%或更多。本研究结果表明，该方案是一种通过结构化的、基于远程医疗的肥胖管理方法来提高治疗性医学减重效果的新方法。
